N-[2-(4-{[4-(cyclobutylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}-11-azatricyclo[6.2.1.0^{2,7}]undeca-2(7),3,5-trien-11-yl)-2-oxoethyl]acetamide

• ChemBase ID: 73200
• Molecular Formular: C23H25F3N6O2
• Molecular Mass: 474.4788096
• Monoisotopic Mass: 474.19910873
• SMILES: c12c(cc(cc1)Nc1nc(c(cn1)C(F)(F)F)NC1CCC1)C1N(C2CC1)C(=O)CNC(=O)C
• Canonical SMILES: CC(=O)NCC(=O)N1C2CCC1c1c2ccc(c1)Nc1ncc(c(n1)NC1CCC1)C(F)(F)F
• InChI: InChI=1S/C23H25F3N6O2/c1-12(33)27-11-20(34)32-18-7-8-19(32)16-9-14(5-6-15(16)18)30-22-28-10-17(23(24,25)26)21(31-22)29-13-3-2-4-13/h5-6,9-10,13,18-19H,2-4,7-8,11H2,1H3,(H,27,33)(H2,28,29,30,31)
• InChIKey: RYYNGWLOYLRZLK-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: N-[2-(4-{[4-(cyclobutylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}-11-azatricyclo[6.2.1.0^{2,7}]undeca-2(7),3,5-trien-11-yl)-2-oxoethyl]acetamide
• IUPAC Traditional name: N-[2-(4-{[4-(cyclobutylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}-11-azatricyclo[6.2.1.0^{2,7}]undeca-2(7),3,5-trien-11-yl)-2-oxoethyl]acetamide
• Synonyms: PF-03814735

Database IDs

• CAS Number: 942487-16-3
• PubChem SID: 162038120
• PubChem CID: 49830590

CALCULATED PROPERTIES

• Acid pKa: 12.570943
• H Acceptors: 6
• H Donor: 3
• LogD (pH = 5.5): 2.2755015
• LogD (pH = 7.4): 2.3619971
• Log P: 2.3632314
• Molar Refractivity: 120.5011 cm^3
• Polarizability: 43.894352 Å^3
• Polar Surface Area: 99.25 Å^2
• Rotatable Bonds: 7
• Lipinski's Rule of Five: true

PROPERTIES

Safety Information

• Storage Condition: -20°C

Pharmacology Properties

• Target: Aurora

Product Information

• Salt Data: Free Base

DETAILS

Selleck Chemicals - S2725

Research Area

• Description: Cancer

Biological Activity

• Description: PF-03814735 is a novel, potent and reversible inhibitor of both Aurora A and Aurora B with IC50 of 0.8 nM and 5 nM, respectively.
• Targets: Aurora A; Aurora B; Flt1; FAK; TrkA
• IC50: 0.8 nM; 5 nM; 10 nM; 22 nM; 30 nM ^[1]
• In Vitro: In intact cells, the inhibitory activity of PF-03814735 on the Aurora1 and Aurora2 kinases reduces levels of phospho-Aurora1 (Thr 232, a sensitive marker of Aurora1 activity, with IC50 ~ 20 nM), phosphohistone H3 (with IC50 ~ 50 nM), and phospho-Aurora2 (with IC50 ~150 nM). PF-03814735 produces a block in cytokinesis, resulting in inhibition of cell proliferation and the formation of polyploid multinucleated cells. ^[1] A recent research indicates small cell lung cancer (SCLC) and, to a lesser extent, colon cancer lines are very sensitive to PF-03814735. The status of the Myc gene family and retinoblastoma pathway members significantly correlates with the efficacy of PF-03814735. ^[1]
• In Vivo: Once-daily oral dosing of ≥20 mg/kg of PF-03814735 for 10 days to mice bearing HCT-116 xenografts resulted in statistically significant and dose-dependent tumor growth inhibition of ≥50% relative to vehicle-treated mice. The inhibition is associated with a reduction in phosphorylated histone H3 levels. Significant single-agent antitumor efficacy is observed in five additional xenograft tumor models, including A2780 ovarian carcinoma, MDA-MB-231 breast carcinoma, colo-205 and SW620 colorectal carcinomas, and HL-60 acute promyelocytic leukemia. ^[1] In vivo experiments with two SCLC xenograft models confirms the sensitivity of Myc gene-driven models to PF-03814735 and a possible schedule dependence of MYC/c-Myc-driven tumors. ^[1]

Combination Therapy

• Description: The combination of PF-03814735 and docetaxel in xenograft mouse tumor models shows additive tumor growth inhibition. ^[1]

Protocol

• Protocol: Kinase Assay ^[1]
• Recombinant Kinase Assays: Aurora1 and Aurora2 proteins are produced as full-length His-tag recombinant proteins expressed in insect cells. For the Aurora2 kinase assay, phosphorylation of the substrate peptide by recombinant Aurora2 protein is assessed by a Z'-LYTE assay at 3 to 300 μM ATP and various concentrations of PF-03814735 over 60 minutes, at a substrate peptide concentration of 2 μM (biotinylated LRRWSLG, ×4). Phosphorylation is linear over this time for all conditions. For the Aurora1 kinase assay, phosphorylation of the substrate peptide by recombinant Aurora1 protein is assessed by a scintillation proximity assay in a 96-well plate format in which the incorporation of ^33P into the peptide substrate (biotinylated LRRWSLG, ×4) is measured by capturing the peptide on a streptavidin scintillation proximity assay bead.
• Protocol: Cell Assay ^[1]
• Cell Lines: HCT-116 cell
• Concentrations: 300 nM
• Incubation Time: 4, 8, 12, 24, 48, or 72 hours
• Methods: Cell lines are grown in appropriate media and evaluated after 48 h of exposure to either PF-03814735 or vehicle, followed by cell number determination in a Coulter Counter. Proliferation (as measured by an increase in cell number) is expressed as a percent of untreated controls. To evaluate the PF-03814735 exposure time required for antiproliferative activity, HL-60 cell cultures are cultured in RPMI medium supplemented with 15% heat-inactivated fetal bovine serum and exposed to various PF-03814735 concentrations for 4, 8, 12, 24, and 48 hours, followed by a washout step and incubation with growth media without PF-03814735 for the remainder of the 72-h assay period. Continuous exposure to PF-03814735 for 72 hours is also evaluated. Cell counts are determined by a Coulter Counter.
• Protocol: Animal Study ^[1]
• Animal Models: HCT116 tumors are implanted s.c. on the right flank of nude mice.
• Formulation: PF-03814735 is formulated as a solution in cremophor EL [cremophor/ethanol/0.9% saline (12.5%/12.5%/75%)].
• Doses: 10, 20, 30 mg/kg
• Administration: Administered orally

References

• References: [1] Jani JP, et al, Mol Cancer Ther, 2010, 9(4), 883-894.
• References: [2] Hook KE, et al, Mol Cancer Ther, 2012, 11(3), 710-719.

REFERENCES

• Jani JP, et al, Mol Cancer Ther, 2010, 9(4), 883-894.
• Hook KE, et al, Mol Cancer Ther, 2012, 11(3), 710-719.